IP Verse

Use Of Dpp Iv Inhibitors - EP2397142

The patent EP2397142 was granted to Boehringer Ingelheim on Jul 27, 2022. The application was originally filed on May 3, 2007 under application number EP11179908A. The patent is currently recorded with a legal status of "Revoked".

EP2397142

BOEHRINGER INGELHEIM
Application Number
EP11179908A
Filing Date
May 3, 2007
Status
Revoked
May 29, 2025
Grant Date
Jul 27, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKApr 27, 2023ELKINGTON AND FIFEADMISSIBLE
STADA ARZNEIMITTELApr 26, 2023KERNEBECKADMISSIBLE
KRAUS & LEDERER PARTGMBBApr 25, 2023KRAUS & LEDERER PARTGMBBADMISSIBLE
POLPHARMAApr 19, 2023HAMM & WITTKOPPADMISSIBLE
SANDOZApr 13, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (152) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0564409
DESCRIPTIONEP0978279
DESCRIPTIONJP2003012686
DESCRIPTIONJP2004196702
DESCRIPTIONJP2004196788
DESCRIPTIONJP2004359630
DESCRIPTIONJP2005170939
DESCRIPTIONJP2005247834
DESCRIPTIONUS2003195243
DESCRIPTIONUS2004002495
DESCRIPTIONUS2005245532
DESCRIPTIONUS2005245533
DESCRIPTIONUS2005245534
DESCRIPTIONUS2005261302
DESCRIPTIONUS2006063722
DESCRIPTIONUS5093330
DESCRIPTIONUS5998463
DESCRIPTIONWO0058293
DESCRIPTIONWO0116147
DESCRIPTIONWO0127128
DESCRIPTIONWO0144216
DESCRIPTIONWO0168660
DESCRIPTIONWO0174834
DESCRIPTIONWO0174835
DESCRIPTIONWO0183465
DESCRIPTIONWO0183478
DESCRIPTIONWO0185706
DESCRIPTIONWO0185707
DESCRIPTIONWO02053573
DESCRIPTIONWO02064606
DESCRIPTIONWO02068439
DESCRIPTIONWO02068440
DESCRIPTIONWO0208209
DESCRIPTIONWO02083066
DESCRIPTIONWO02088157
DESCRIPTIONWO02098893
DESCRIPTIONWO0214312
DESCRIPTIONWO0228872
DESCRIPTIONWO0236602
DESCRIPTIONWO0244192
DESCRIPTIONWO0246173
DESCRIPTIONWO0248106
DESCRIPTIONWO03000262
DESCRIPTIONWO03000267
DESCRIPTIONWO03000712
DESCRIPTIONWO03011880
DESCRIPTIONWO03015774
DESCRIPTIONWO03020737
DESCRIPTIONWO03047626
DESCRIPTIONWO03055482
DESCRIPTIONWO03080585
DESCRIPTIONWO03080635
DESCRIPTIONWO03095438
DESCRIPTIONWO03099836
DESCRIPTIONWO2004002481
DESCRIPTIONWO2004005281
DESCRIPTIONWO2004013118
DESCRIPTIONWO2004014931
DESCRIPTIONWO2004014932
DESCRIPTIONWO2004018468
DESCRIPTIONWO2004018491
DESCRIPTIONWO2004019958
DESCRIPTIONWO2004050658
DESCRIPTIONWO2004052902
DESCRIPTIONWO2004052903
DESCRIPTIONWO2004058790
DESCRIPTIONWO2004080990
DESCRIPTIONWO2004087727
DESCRIPTIONWO2004089966
DESCRIPTIONWO2004089967
DESCRIPTIONWO2004099230
DESCRIPTIONWO2004113359
DESCRIPTIONWO2005011592
DESCRIPTIONWO2005012242
DESCRIPTIONWO2005012243
DESCRIPTIONWO2005012318
DESCRIPTIONWO2005012326
DESCRIPTIONWO2005021566
DESCRIPTIONWO2005063785
DESCRIPTIONWO2005085237
DESCRIPTIONWO2005085246
DESCRIPTIONWO2005085265
DESCRIPTIONWO2005085267
DESCRIPTIONWO2005092877
DESCRIPTIONWO2005095373
DESCRIPTIONWO2005110992
DESCRIPTIONWO2005116002
DESCRIPTIONWO2005118538
DESCRIPTIONWO2006000371
DESCRIPTIONWO2006002349
DESCRIPTIONWO2006002350
DESCRIPTIONWO2006010546
DESCRIPTIONWO2006012173
DESCRIPTIONWO2006012226
DESCRIPTIONWO2006012227
DESCRIPTIONWO2006017542
DESCRIPTIONWO2006020598
DESCRIPTIONWO2006024627
DESCRIPTIONWO2006024628
DESCRIPTIONWO2006029769
DESCRIPTIONWO2006030804
DESCRIPTIONWO2006030805
DESCRIPTIONWO2006037501
DESCRIPTIONWO2006040329
DESCRIPTIONWO2006041976
DESCRIPTIONWO2006048330
DESCRIPTIONWO2006048331
DESCRIPTIONWO2006048750
DESCRIPTIONWO2006049952
DESCRIPTIONWO2006050908
DESCRIPTIONWO2006051662
DESCRIPTIONWO2006053024
DESCRIPTIONWO2006055752
DESCRIPTIONWO2006066109
DESCRIPTIONWO2006068199
DESCRIPTIONWO2006068991
DESCRIPTIONWO2006068992
DESCRIPTIONWO2006074244
DESCRIPTIONWO2006074330
DESCRIPTIONWO2006080533
DESCRIPTIONWO2006094633
DESCRIPTIONWO2006095822
DESCRIPTIONWO2006097337
DESCRIPTIONWO2007005572
DESCRIPTIONWO2007007041
DESCRIPTIONWO2007007042
DESCRIPTIONWO2007007886
DESCRIPTIONWO2007007910
DESCRIPTIONWO2007017649
DESCRIPTIONWO9835958
OPPOSITIONCA2496249
OPPOSITIONCA2508233
OPPOSITIONCA2555050
OPPOSITIONCA2576294
OPPOSITIONCA2651019
OPPOSITIONEP2015754
OPPOSITIONWO0172290
OPPOSITIONWO2004018468
OPPOSITIONWO2004050658
OPPOSITIONWO2005049022
OPPOSITIONWO2005085246
OPPOSITIONWO2005119526
OPPOSITIONWO2005120576
OPPOSITIONWO2006029769
OPPOSITIONWO2007128761
SEARCHWO0172290
SEARCHWO2004018468
SEARCHWO2004050658
SEARCHWO2005049022
SEARCHWO2005085246
SEARCHWO2005120576
SEARCHWO2006029769

Non-Patent Literature (NPL) Citations (26) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Journal of the American Medical Association, (20010000), vol. 285, pages 2486 - 2497-
OPPOSITION- Anonymous, "TRAJENTA - ANHANG I ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS", European Commission, (20160322), European Commission, (20240415), XP093151855-
OPPOSITION- David M Kendall , Dennis Kim, David Maggs, "Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: A Review of Emerging Therapies for Type 2 Diabetes", Diabetes Technology & Therapeutics, (20060601), vol. 8, no. 3, doi:10.1089/dia.2006.8.385, ISSN 1520-9156, pages 385 - 396, XP093043743-
OPPOSITION- E Standl , S Eckert , C Fuchs , D Horslkotte , H U Janka , H G Lengeling , R Pelzoldt , M Redaelli , P Sawicki , W A Scherbaum , R H Strasser , D Tschope, "Diabetes und Herz", Deutsche Evidenzbasierte Diabetes-Leitlinien (DDG), (20020507), pages 1 - 25, XP093043744-
OPPOSITION- Kendall David M, Et Al, "Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: A Review of Emerging Therapies for Type 2 Diabetes", Diabetes Technology & Therapeutics, (20060601), vol. 8, no. 3, pages 385 - 396, XP093043743-
OPPOSITION- Standl E, "Diabetes und Herz", Deutsche Evidenzbasierte Diabetes-Leitlinien (DDG), (20020507), pages 1 - 25, XP093043744-
OPPOSITION- Standl E, Et Al, "Deutsche Evidenzbasierte Diabetes-Leitlinien (DDG) „Diabetes und Herz”", (20020507), pages 1 - 25, XP093043744-
OPPOSITION- Rosenstock Julio, Perkovic Vlado, Johansen Odd Erik, Cooper Mark E., Kahn Steven E., Marx Nikolaus, Alexander John H., Pencina Michael, Toto Robert D., Wanner Christoph, Zinman Bernard, Woerle Hans Juergen, Baanstra David, Pfarr Egon, Schnaidt Sven, Meinicke Thomas, George Jyothis T., Von Eynatten Maximilian, Mcguire Darren K., "Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk : The CARMELINA Randomized Clinical Trial", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US , (20190101), vol. 321, no. 1, doi:10.1001/jama.2018.18269, ISSN 0098-7484, pages 69 - 79, XP093142558
OPPOSITION- Rosenstock Julio, Kahn Steven E., Johansen Odd Erik, Zinman Bernard, Espeland Mark A., Woerle Hans J., Pfarr Egon, Keller Annett, Mattheus Michaela, Baanstra David, Meinicke Thomas, George Jyothis T., Von Eynatten Maximilian, Mcguire Darren K., Marx Nikolaus, "Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes : The CAROLINA Randomized Clinical Trial", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US , (20190924), vol. 322, no. 12, doi:10.1001/jama.2019.13772, ISSN 0098-7484, pages 1155 - 1166, XP093142563
OPPOSITION- Eckhardt, M. ; Hauel, N. ; Himmelsbach, F. ; Langkopf, E. ; Nar, H. ; Mark, M. ; Tadayyon, M. ; Thomas, L. ; Guth, B. ; Lotz, R., "3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors", Bioorganic & Medicinal Chemistry Letters, Amsterdam NL , (20080601), vol. 18, no. 11, doi:10.1016/j.bmcl.2008.04.075, ISSN 0960-894X, pages 3158 - 3162, XP022711188
OPPOSITION- P. CLIFTON, "Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?", Clin . Ther, (20140000), vol. 36, no. 12, doi:10.1016/j.clinthera.2014.10.009, pages 2072 - 2079, XP029115756
OPPOSITION- J. B. MARKS, "Cardiovascular risk in diabetes - a brief review", Journal of Diabetes and its Complications, (20000000), vol. 14, doi:10.1016/S1056-8727(00)00065-9, pages 108 - 115, XP093128893
OPPOSITION- Haffner Steven M; Seppo Lehto; Tapani Rönnemaa; Kalevi Pyörälä , Markku Laakso, "Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction", The New England Journal of Medicine, (19980723), vol. 339, no. 7, doi:10.1056/NEJM199807233390404, pages 229 - 234, XP055849076
OPPOSITION- S. Kroller-Schon, Knorr M., Hausding M., Oelze M., Schuff A., Schell R., Sudowe S., Scholz A., Daub S., Karbach S., Kossmann S., Gori T., Wenzel P., Schulz E., Grabbe S., Klein T., Munzel T., Daiber A., "Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition", Cardiovascular Research, (20121001), vol. 96, no. 1, doi:10.1093/cvr/cvs246, ISSN 0008-6363, pages 140 - 149, XP055073359
OPPOSITION- Shiraki A, Oyama J, Shimizu T, Node N, "The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice", European Heart Journal, Oxford University Press, GB , (20221003), vol. 43, no. Supplement_2, doi:10.1093/eurheartj/ehac544.2682, ISSN 0195-668X, pages 2682 - 2682, XP093142569
OPPOSITION- J Calles-Escandon, E Garcia-Rubi, S Mirza, A Mortensen, "Type 2 diabetes: one disease, multiple cardiovascular risk factors", CORONARY ARTERY DISEASE., CURRENT SCIENCE LTD., GB, GB , (19990101), vol. 10, no. 1, doi:10.1097/00019501-199901000-00004, ISSN 0954-6928, pages 23 - 30, XP009553445
OPPOSITION- Thomas Leo; Eckhardt Matthias; Langkopf Elke; Tadayyon Moh; Himmelsbach Frank; Mark Michael, "(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quina zolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors", Journal of pharmacology and experimental therapeutics, US , (20080401), vol. 325, no. 1, doi:10.1124/jpet.107.135723, ISSN 0022-3565, pages 175 - 182, XP009105508
OPPOSITION- Nyström Thomas, Gutniak Mark K., Zhang Qimin, Zhang Fan, Holst Jens Juul, Ahrén Bo, Sjöholm Åke, "Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease", American journal of physiology endocrinology and metabolism, US , (20041201), vol. 287, no. 6, doi:10.1152/ajpendo.00237.2004, ISSN 0193-1849, pages E1209 - E1215, XP093144658
OPPOSITION- Mcguire Darren K., Alexander John H., Johansen Odd Erik, Perkovic Vlado, Rosenstock Julio, Cooper Mark E., Wanner Christoph, Kahn Steven E., Toto Robert D., Zinman Bernard, Baanstra David, Pfarr Egon, Schnaidt Sven, Meinicke Thomas, George Jyothis T., Von Eynatten Maximilian, Marx Nikolaus, "Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA", Circulation, American Heart Association, US , (20190115), vol. 139, no. 3, doi:10.1161/CIRCULATIONAHA.118.038352, ISSN 0009-7322, pages 351 - 361, XP093142549
OPPOSITION- Rosenstock Julio, Marx Nikolaus, Neubacher Dietmar, Seck Thomas, Patel Sanjay, Woerle Hans-Juergen, Johansen Odd Erik, "Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events", Cardiovasc Diabetology, BIOMED CENTRAL, LONDON, GB, (20151201), vol. 14, no. 1, doi:10.1186/s12933-015-0215-2, ISSN 1475-2840, pages 1 - 15, XP093142551
OPPOSITION- Fadini Gian Paolo, Bonora Benedetta Maria, Albiero Mattia, Zaninotto Martina, Plebani Mario, Avogaro Angelo, "DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes", Cardiovasc Diabetology, BIOMED CENTRAL,, LONDON, GB, (20171201), vol. 16, no. 1, doi:10.1186/s12933-017-0507-9, ISSN 1475-2840, pages 1 - 7, XP093142539
OPPOSITION- Mu Liying, Wang Zhuo, Ren Jinmei, Xiong Xiaowei, Jin Zening, Liu Xin, "Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus", Diabetology & Metabolic Syndrome, BioMed Central Ltd, London, UK , (20221201), vol. 14, no. 1, doi:10.1186/s13098-022-00797-x, ISSN 1758-5996, pages 1 - 9, XP093142542
OPPOSITION- M Tadayyon , S A Smith, "Insulin sensitisation in the treatment of Type 2 diabetes", Expert Opinion on Investigational Drugs, UK , (20030301), vol. 12, no. 3, doi:10.1517/13543784.12.3.307, ISSN 1354-3784, pages 307 - 324, XP008048351
OPPOSITION- TADAYYON M, SMITH S A, "INSULIN SENSITISATION IN THE TREATMENT OF TYPE 2 DIABETES", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK , (20030301), vol. 12, no. 03, doi:10.1517/13543784.12.3.307, ISSN 1354-3784, pages 307 - 324, XP008048351
OPPOSITION- Markku Laakso, "Hyperglycemia and Cardiovascular Disease in Type 2 Diabetes", Diabetes, (19990501), vol. 48, no. 5, doi:10.2337/diabetes.48.5.937, pages 937 - 942, XP093087612
OPPOSITION- Batchu Sri Nagarjun, Yerra Veera Ganesh, Liu Youan, Advani Suzanne L., Klein Thomas, Advani Andrew, "The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans", International journal of molecular sciences, Basel, CH , (20200811), vol. 21, no. 16, doi:10.3390/ijms21165756, ISSN 1422-0067, pages 1 - 14, XP093144655

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents